Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences(US:TYRA) Prnewswire·2026-05-13 20:00- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 - - Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to date) - - Initial Ph2 data readout from safety sentinel cohort in BEACH301 expected in Q4 2026 (4th dose level cleared) - Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights Accessibility State ...